Reactwise raises £2.6m in pre-seed funding to advance AI-driven pharmaceutical manufacturing.
The pre-seed round was backed by participants including Y Combinator and the UK government.
Reactwise provides an artificial intelligence platform for automated robotic laboratories designed to accelerate pharmaceutical manufacturing and research. The system integrates with electronic lab notebooks to optimise scalable chemical processes and reduce trial-and-error workloads.
Reactwise has secured £2.6m in pre-seed funding from backers including Y Combinator and the UK government. The capital will support the company as it develops artificial intelligence-driven robotic laboratories and software designed to accelerate pharmaceutical manufacturing research.
The business recently completed Y Combinator's summer 2024 batch and currently runs 12 pilot studies with major pharmaceutical companies. Its technology aims to streamline the drug development pipeline by predicting scalable manufacturing processes and reducing experimental workloads.
From the founder
"The discovery of novel pharmaceuticals is one of our most important weapons in fighting disease. However, the drug development pipeline is often driven by trial-and-error and held up for many months during the identification of scalable manufacturing processes, delaying clinical trials. Our AI-powered models learn from historical data, cutting up to 95% of experimental work and accelerating these workflows by 30x."
Alexander Pomberger
CEO and Co-Founder at Reactwise
Use of funds
- 01Fund research and development